“It may be that, some ages hence... the restoration of grey hairs to juvenility and the renewing of the exhausted marrow may at length be elicited without a miracle”
Joseph Glanvill,
1661AD
Local Immune Tolerance from cytotrophoblast-derived endovascular cells
Axordia has developed a patent protected method for producing large numbers of high purity cytotrophoblast-derived endovascular cells. These cell lines promote the critical changes in the uterus during the first stages of pregnancy and have three key and extremely valuable characteristics – they bring about a localised immune-privileged site, possess anti-inflammatory properties and promote blood vessel growth. They play a significant role in preventing the rejection of the forming foetus and in developing the vascular architecture supporting the placenta.
Endovascular cells express an immune tolerogenic factor, soluble HLA-G that can neutralise T cell-mediated immune responses. This makes the cells potential candidates for therapeutic uses where localised immune tolerogenesis would be desirable rather than drug-induced systemic immune suppression that can leave patients vulnerable to secondary infections.
Axordia is developing applications for its endovascular cells in the following areas:
- The development of a third generation regenerative coronary stent application to reduce stent-induced restenosis and promote blood vessel repair
- Co-transplantation with other engineered therapeutic cells or organs to provide localised immune suppression and improved engraftment